The RTGel™ Technology Platform:
RTGel™, UroGen’s novel technology platform, is a reverse thermal hydrogel, which, unlike the general characteristics of most forms of matter, is liquid at lower temperatures and converts into gel form when warmed to body temperature. These characteristics are designed to promote ease of delivery into and retention of drugs in body cavities, including the bladder and the upper urinary tract, by conforming to the anatomy of the target organ while preventing rapid excretion of the drug. The following images show how the RTGel technology is designed to work:
RTGel-based drug formulations are designed to overcome the anatomical and physiological challenges that have historically contributed to the lack of drug development for the treatment of urothelial cancer, ultimately improving the therapeutic potential of active drugs.